๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention

โœ Scribed by Dr Leonard Berg; J. Philip Miller; Jack Baty; Eugene H. Rubin; John C. Morris; Gary Figiel


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
758 KB
Volume
31
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Aphasia in senile dementia of the alzhei
โœ Kathy Faber-Langendoen; Dr. John C. Morris; John W. Knesevich; Emily LaBarge; J. ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 658 KB
Mild senile dementia of the Alzheimer ty
โœ Dr Leonared Berg; Deborah S. Smith; John C. Morris; J. Philip Miller; Eugene H. ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 444 KB ๐Ÿ‘ 1 views

## Abstract Sixtyโ€six subjects diagnosed by validated criteria as having senile dementia of the Alzheimer type (SDAT) were assessed with clinical measures commonly used to study dementia. The severity of the SDAT was mild in 24, moderate in 24, and severe in 18. The data from these three groups in

CT study in senile dementia of Alzheimer
โœ Kenichi Ueyama; Hiroshi Fukuzako; Tsuyoshi Fukuzako; Yoshirou Hokazono; Kouzou T ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 419 KB

We evaluated 14 patients with senile dementia of Alzheimer type (SDAT) and 15 age-matched normal elderly controls using psychological tests and computed tomography scans. The low-density rate (LDR) was used as an index of brain atrophy. SDAT patients had significantly higher scores on the Hasegawa D

Milacemide: Safety assessment in senile
โœ Maurice W. Dysken; T. Daniel Fakouhi; Stacy S. Skare; Joseph Mendels; Peter LeWi ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 381 KB

Milacemide, both an MAO-B inhibitor and a prodrug for glycine, has demonstrated cognitive enhancing effects in animal models, in cognitively intact young and elderly, and has been suggested as a potential treatment for senile dementia of the Alzheimer type (SDAT). This multicenter open-label trial e